The antiglomerular basement membrane disease : treatments and outcomes
K. Hirayama,K. Yamagata
Abstract:Introduction Antiglomerular basement membrane (anti-GBM) disease is a rare autoimmune disorder characterized by rapidly progressive glomerulonephritis (RPGN) with diffuse crescentic formation on renal biopsy, and it is a well-characterized cause of glomerulonephritis. Although the effectiveness of treatment using therapeutic plasma exchange combined with immunosuppressive agents to improve renal function has been reported, the prognosis for patients with this disease is poor. To improve the prognosis, it may be necessary to detect this disease in earlier stages and to treat it without delay. This critical review discusses the treatments and outcomes of anti-GBM disease. Conclusion Anti-GBM disease is rare, but the treatment has been reported to improve renal function. This disease needs to be detected in its early stages to tackle the life cycle of the disease. Introduction Antiglomerular basement membrane (anti-GBM) disease is a rare autoimmune disorder characterized by rapidly progressive glomerulonephritis (RPGN) with diffuse crescentic formation on renal biopsy, and it is a well-characterized cause of glomerulonephritis. Anti-GBM disease is defined as the presence of serum autoantibodies to the noncollagenous domain of the alpha 3 chain of type IV collagen or a linear binding of IgG to glomerular capillary walls as detected by direct immunofluorescence in patients with RPGN. Although effective treatments to improve renal function have been reported, the prognosis of patients with this disease is poor. This critical review focuses on treatments and outcomes of antiGBM disease in order to improve the prognosis of the disease. Discussion The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964), and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies. Treatments As the pathogenesis of anti-GBM disease became clear, treatment regimens were designed to remove the circulating pathogenic anti-GBM antibodies by therapeutic plasma exchange, attenuating the pathogenic antibody-mediated glomerular inflammatory responses by administration of corticosteroids and suppressing further production of these pathogenic antibodies by the use of immunosuppressive agents. Therapeutic plasmapheresis To remove the circulating pathogenic anti-GBM antibodies, therapeutic plasma exchange is recommended as the initial treatment. The effectiveness of therapeutic plasmapheresis for improving renal function has been reported. Several regimens were reported (Table 1)1–9, and plasma exchange of 4 L of plasma for 5% human albumin was most commonly performed daily for 14 days or until the circulating anti-GBM antibodies were no longer detected1. In the presence of alveolar haemorrhage, 300– 400 ml of fresh-frozen plasma was given at the end of each treatment. To reduce the plasma replacement, anti-GBM antibody removal has been modified. Immunoadsorption to remove circulating IgG without the need for protein substitution during daily treatments may also be beneficial in Goodpasture’s disease. Anecdotal case reports suggest that it may be an alternative to plasmapheresis in patients with severe renal failure10. A case report of Goodpasture’s syndrome treated with double-filtration plasmapheresis combined with immunosuppression therapy11 showed that the removal efficiency for the anti-GBM antibody was 24%–60% for each procedure. Corticosteroids To attenuate the pathogenic antibody-mediated glomerular inflammatory responses, corticosteroid is also a key element of this treatment. According to the most commonly used regimens, oral dosing of prednisolone at 1 mg/kg/day of ideal body weight (maximum 80 mg daily) continues for at least 2 weeks, after which the dose is reduced * Corresponding author Email: k-hira@naritasekijyuji.jp 1 Department of Nephrology, Japanese Red Cross Narita Hospital, Narita, Chiba 2 Department of Nephrology, Tokyo Medical University Ibaraki Medical Center, Ami, Ibaraki, Japan 3 Department of Nephrology, University of Tsukuba, Tsukuba, Ibaraki, Japan